Eplerenone for heart injury without blocked heart arteries
Part of Heart & circulation clinical trials.
This Phase 2 study tests whether eplerenone can improve outcomes after a heart attack (or similar heart injury) when coronary angiography shows no blocked heart arteries. It focuses on people with added cardiovascular risk factors and evaluates how well the treatment works for heart recovery and strain on the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have had a recent heart attack or heart injury, with coronary angiography showing no obstructive (blocked) coronary arteries
- Have at least one cardiovascular risk factor such as age over 70, atrial fibrillation, diabetes, current smoking, prior heart attack, treated high blood pressure, reduced kidney function (eGFR 30–60), or COVID-19 (confirmed or suspected)
- Be able to have the planned heart tests, including coronary angiography and heart imaging (cardiac MRI)
- Avoid certain medicines: do not take an MRA already, and avoid specific drug interactions (for example some anti-fungals, antivirals, certain antibiotics, nefazodone, or the ACE inhibitor + ARB combination)
- Kidney function must be at least eGFR 30 (mL/min/1.73m²), and you should not have severe liver problems or significant heart failure signs after the heart injury
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether eplerenone (a blood pressure pill) can improve heart function in people who have had a kidney transplant and are taking cyclosporine or tacrolimus. It may help reduce the strain on the heart caused by these anti-rejection medicines.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This study tests whether a medicine called eplerenone can help prevent atrial fibrillation from coming back in people who also have structural heart disease (changes in the heart's structure). If you have had episodes of irregular heartbeat that stopped, this drug might lower the chance of them returning.
This study looks at how mineralocorticoid-related hormone signaling affects small heart blood vessels and how efficiently the heart works in people with high blood pressure. It may help doctors understand which treatments could improve heart function in hypertension.
This trial tests whether eplerenone can slow the progression of blood vessel (vasculature) problems in people who have had a kidney transplant. You may be eligible if you are older, stable on your transplant medicines, and have higher peripheral artery blood pressure readings.
This study tests if a medication called a mineralocorticoid receptor antagonist (MRA) can help improve heart function in women who had preeclampsia and now have high blood pressure and signs of heart thickening.
Hear when a new Myocardial Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.